

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER
WORLD HEALTH ORGANIZATION



IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS

VOLUME 50
PHARMACEUTICAL DRUGS

1990

I A R C
L Y O N
F R A N C E



WORLD HEALTH ORGANIZATION

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

IARC MONOGRAPHS
ON THE
EVALUATION OF CARCINOGENIC
RISKS TO HUMANS

Pharmaceutical Drugs

VOLUME 50

This publication represents the views and expert opinions
of an IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans,
which met in Lyon,

17-24 October 1989

1990

IARC MONOGRAPHS

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. In 1980 and 1986, the programme was expanded to include the evaluation of the carcinogenic risks associated with exposures to complex mixtures and other agents.

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed, and on specific exposure situations; to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields; and to indicate where additional research efforts are needed.

This project is supported by PHS Grant No. 6 UO1 CA33193-06 awarded by the US National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the Commission of the European Communities.

©International Agency for Research on Cancer 1990

ISBN 92 832 1250 9

ISSN 0250-9555

All rights reserved. Application for rights of reproduction or translation, in part or *in toto*, should be made to the International Agency for Research on Cancer.

Distributed for the International Agency for Research on Cancer
by the Secretariat of the World Health Organization

PRINTED IN THE UK

CONTENTS

NOTE TO THE READER	5
LIST OF PARTICIPANTS	7
PREAMBLE	
Background	11
Objective and Scope	11
Selection of Topics for Monographs	12
Data for Monographs	13
The Working Group	13
Working Procedures	14
Exposure Data	14
Biological Data Relevant to the Evaluation of Carcinogenicity to Humans	16
Evidence for Carcinogenicity in Experimental Animals	17
Other Relevant Data in Experimental Systems and in Humans	19
Evidence for Carcinogenicity in Humans	21
Summary of Data Reported	24
Evaluation	25
References	29
GENERAL REMARKS	33
THE MONOGRAPHS	
Antineoplastic and immunosuppressive agents	
Azacitidine	47
Chlorozotocin	65
Ciclosporin	77
Prednimustine	115
Thiotepa	123
Trichlormethine (Trimustine hydrochloride)	143

CONTENTS

Antimicrobial agents

Ampicillin	153
Chloramphenicol	169
Nitrofurantoin (Nitrofurazone)	195
Nitrofurantoin	211

Other drugs

Cimetidine	235
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	265
Furosemide (Frusemide)	277
Hydrochlorothiazide	293
Paracetamol (Acetaminophen)	307

SUMMARY OF FINAL EVALUATIONS	333
------------------------------------	-----

APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS	335
--	-----

APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS	337
---	-----

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49	385
--	-----

CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	387
--	-----



WORLD HEALTH ORGANIZATION

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

IARC MONOGRAPHS
ON THE
EVALUATION OF CARCINOGENIC
RISKS TO HUMANS

Pharmaceutical Drugs

VOLUME 50

This publication represents the views and expert opinions
of an IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans,
which met in Lyon,

17-24 October 1989

1990

IARC MONOGRAPHS

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. In 1980 and 1986, the programme was expanded to include the evaluation of the carcinogenic risks associated with exposures to complex mixtures and other agents.

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed, and on specific exposure situations; to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields; and to indicate where additional research efforts are needed.

This project is supported by PHS Grant No. 6 UO1 CA33193-06 awarded by the US National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the Commission of the European Communities.

©International Agency for Research on Cancer 1990

ISBN 92 832 1250 9

ISSN 0250-9555

All rights reserved. Application for rights of reproduction or translation, in part or *in toto*, should be made to the International Agency for Research on Cancer.

Distributed for the International Agency for Research on Cancer
by the Secretariat of the World Health Organization

PRINTED IN THE UK

CONTENTS

NOTE TO THE READER	5
LIST OF PARTICIPANTS	7
PREAMBLE	
Background	11
Objective and Scope	11
Selection of Topics for Monographs	12
Data for Monographs	13
The Working Group	13
Working Procedures	14
Exposure Data	14
Biological Data Relevant to the Evaluation of Carcinogenicity to Humans	16
Evidence for Carcinogenicity in Experimental Animals	17
Other Relevant Data in Experimental Systems and in Humans	19
Evidence for Carcinogenicity in Humans	21
Summary of Data Reported	24
Evaluation	25
References	29
GENERAL REMARKS	33
THE MONOGRAPHS	
Antineoplastic and immunosuppressive agents	
Azacitidine	47
Chlorozotocin	65
Ciclosporin	77
Prednimustine	115
Thiotepa	123
Trichlormethine (Trimustine hydrochloride)	143

CONTENTS

Antimicrobial agents

Ampicillin	153
Chloramphenicol	169
Nitrofurantoin (Nitrofurazone)	195
Nitrofurantoin	211

Other drugs

Cimetidine	235
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	265
Furosemide (Frusemide)	277
Hydrochlorothiazide	293
Paracetamol (Acetaminophen)	307

SUMMARY OF FINAL EVALUATIONS	333
------------------------------------	-----

APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS	335
--	-----

APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS	337
---	-----

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49	385
--	-----

CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	387
--	-----

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.

IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: PHARMACEUTICAL DRUGS

Lyon, 17-24 October 1989

LIST OF PARTICIPANTS

Members

- I.N. Chernozemsky, National Oncological Centre, Medical Academy, Darvenitza, Sofia 1156, Bulgaria
- L. Fiore-Donati, Istituto di Anatomia e Istologia Patologica, Verona University, Policlinico Borgo Roma, 37100 Verona, Italy
- G.D. Friedman, Division of Research, Kaiser Permanente Medical Care Program, Northern California Region, 3451 Piedmont Avenue, Oakland, CA 94611, USA
- B. Holmberg, Department of Toxicology, National Institute of Occupational Health, 171 84 Solna, Sweden
- L.J. Kinlen, Cancer Research Campaign Epidemiology Unit, University of Edinburgh, 15 George Square, Edinburgh EH8 9JZ, UK
- M. Marselos, Department of Pharmacology, Medical School, University of Ioannina, Ioannina 45110, Greece
- M. Mattila, Department of Clinical Pharmacology, University of Helsinki, Department of Clinical Pharmacology, University of Helsinki, Paasikivenkatu 4, 00250 Helsinki, Finland
- G. Obe, Universität GSH Essen, Fachbereich 9, Department of Genetics, PO Box 103 764, 4300 Essen 1, Federal Republic of Germany
- J.H. Olsen, Danish Cancer Registry, Rosenvaengets Hovedvej 35, Box 839, 2100 Copenhagen Ø, Denmark
- N.V. Popova, Laboratory of Carcinogenic Substances, All-Union Cancer Research Centre, Kashirskoye Shosse 24, 115478 Moscow, USSR

- J.P. Seiler¹, Swiss Federal Research Station for Fruit-Growing, Viticulture and Horticulture, 8820 Wädenswil, Switzerland
- S. Shapiro, Boston University Medical School, Slone Epidemiology Unit, 1371 Beacon Street, Brookline, MA 02146, USA
- S.M. Sieber, Division of Cancer Etiology, National Cancer Institute, Building 31, Room 11A03, Bethesda, MD 20892, USA
- M. Sorsa, Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland (*Vice-Chairperson*)
- R. Stahlmann, Institut für Toxikologie und Embryonal Pharmakologie der Freien Universität Berlin, Garystrasse 1-9, 100 Berlin 33, Federal Republic of Germany
- B. Stewart, Children's Leukaemia and Cancer Research Unit, The Prince of Wales Children's Hospital, High Street, Randwick, NSW 2031, Australia
- F.M. Sullivan, Department of Pharmacology, Guy's Hospital Medical School, London SE1 9RT, UK
- J. Weissinger, Office of Drug Evaluation (HFD-502), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA
- G.M. Williams, American Health Foundation, Dana Road, Valhalla, NY 10595, USA (*Chairman*)
- K. Yokoro, Hiroshima University, Institute of Nuclear Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan

Representatives and observers²

Representative of the International Federation of Pharmaceutical Manufacturers' Associations

- E. Longstaff, Safety Medicines Department, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

Representative of the US Pharmaceutical Manufacturers' Association

- M.J. Tidd, Norwich Eaton Pharmaceuticals Inc., PO Box 191, Norwich, NY 13815-0191, USA

¹Present address: Interkantonale Kontrollstelle für Heilmittel (IKS), Erlachstrasse 8, 3000 Bern, Switzerland

²Unable to attend, M.-Th. van der Venne, Commission of the European Communities, Health and Safety Directorate, Bâtiment Jean Monnet (C4/83), BP 1907, 2920 Luxembourg, Grand Duchy of Luxembourg

Secretariat

- A. Aitio, Laboratory of Biochemistry, Institute of Occupational Health, Arinatie
3, 00370 Helsinki, Finland
- H. Bartsch, Unit of Environmental Carcinogenesis and Host Factors
- X. Bosch, Unit of Field Intervention Studies
- E. Cardis, Unit of Biostatistical Research and Informatics
- J. Cheney, Editorial, Translation and Publication Services
- M. Coleman, Unit of Descriptive Epidemiology
- M. Friesen, Unit of Environmental Carcinogenesis and Host Factors
- E. Heseltine, Montignac, France
- J. Jongen, Unit of Mechanisms of Carcinogenesis
- J. Kaldor, Unit of Biostatistics Research and Informatics
- V. Krutovskikh, Unit of Mechanisms of Carcinogenesis
- K. L'Abbé, Unit of Analytical Epidemiology
- D. McGregor, Unit of Carcinogen Identification and Evaluation
- D. Miettinen, Unit of Carcinogen Identification and Evaluation
- R. Montesano, Unit of Mechanisms of Carcinogenesis
- S. Narod, Unit of Mechanisms of Carcinogenesis
- G. Nordberg, Unit of Carcinogen Identification and Evaluation
- C. Partensky, Unit of Carcinogen Identification and Evaluation
- I. Peterschmitt, Unit of Carcinogen Identification and Evaluation, Geneva,
Switzerland
- D. Shuker, Unit of Environmental Carcinogenesis and Host Factors
- L. Shuker, Unit of Carcinogen Identification and Evaluation
- L. Tomatis, Director
- H. Vainio, Unit of Carcinogen Identification and Evaluation
- J. Wilbourn, Unit of Carcinogen Identification and Evaluation

Secretarial assistance

- J. Cazeaux
- M. Lézère
- S. Reynaud

IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS¹

PREAMBLE

1. BACKGROUND

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme to evaluate the carcinogenic risk of chemicals to humans and to produce monographs on individual chemicals. The *Monographs* programme has since been expanded to include consideration of exposures to complex mixtures of chemicals (which occur, for example, in some occupations and as a result of human habits) and of exposures to other agents, such as radiation and viruses. With Supplement 6(1), the title of the series was modified from *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans* to *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, in order to reflect the widened scope of the programme.

The criteria established in 1971 to evaluate carcinogenic risk to humans were adopted by the working groups whose deliberations resulted in the first 16 volumes of the *IARC Monographs* series. Those criteria were subsequently re-evaluated by working groups which met in 1977(2), 1978(3), 1979(4), 1982(5) and 1983(6). The present preamble was prepared by two working groups which met in September 1986 and January 1987, prior to the preparation of Supplement 7(7) to the *Monographs* and was modified by a working group which met in November 1988(8).

2. OBJECTIVE AND SCOPE

The objective of the programme is to prepare, with the help of international working groups of experts, and to publish in the form of monographs, critical

¹This project is supported by PHS Grant No. 5 UO1 CA33193-07 awarded by the US National Cancer Institute, Department of Health and Human Services, and with a subcontract to Tracor Technology Resources, Inc. Since 1986, this programme has also been supported by the Commission of the European Communities.

reviews and evaluations of evidence on the carcinogenicity of a wide range of human exposures. The *Monographs* may also indicate where additional research efforts are needed.

The *Monographs* represent the first step in carcinogenic risk assessment, which involves examination of all relevant information in order to assess the strength of the available evidence that certain exposures could alter the incidence of cancer in humans. The second step is quantitative risk estimation, which is not usually attempted in the *Monographs*. Detailed, quantitative evaluations of epidemiological data may be made in the *Monographs*, but without extrapolation beyond the range of the data available. Quantitative extrapolation from experimental data to the human situation is not undertaken.

These monographs may assist national and international authorities in making risk assessments and in formulating decisions concerning any necessary preventive measures. The evaluations of IARC working groups are scientific, qualitative judgements about the degree of evidence for carcinogenicity provided by the available data on an agent. These evaluations represent only one part of the body of information on which regulatory measures may be based. Other components of regulatory decisions may vary from one situation to another and from country to country, responding to different socioeconomic and national priorities. *Therefore, no recommendation is given with regard to regulation or legislation, which are the responsibility of individual governments and/or other international organizations.*

The *IARC Monographs* are recognized as an authoritative source of information on the carcinogenicity of chemicals and complex exposures. A users' survey, made in 1988, indicated that the *Monographs* are consulted by various agencies in 57 countries. Each volume is generally printed in 4000 copies for distribution to governments, regulatory bodies and interested scientists. The *Monographs* are also available *via* the Distribution and Sales Service of the World Health Organization.

3. SELECTION OF TOPICS FOR MONOGRAPHS

Topics are selected on the basis of two main criteria: (a) that they concern agents and complex exposures for which there is evidence of human exposure, and (b) that there is some evidence or suspicion of carcinogenicity. The term agent is used to include individual chemical compounds, groups of chemical compounds, physical agents (such as radiation) and biological factors (such as viruses) and mixtures of agents such as occur in occupational exposures and as a result of personal and cultural habits (like smoking and dietary practices). Chemical analogues and compounds with biological or physical characteristics similar to those of suspected carcinogens may also be considered, even in the absence of data on carcinogenicity.